Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

534 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the XELBEVOCT study.
Berruti A, Fazio N, Ferrero A, Brizzi MP, Volante M, Nobili E, Tozzi L, Bodei L, Torta M, D'Avolio A, Priola AM, Birocco N, Amoroso V, Biasco G, Papotti M, Dogliotti L. Berruti A, et al. BMC Cancer. 2014 Mar 14;14:184. doi: 10.1186/1471-2407-14-184. BMC Cancer. 2014. PMID: 24628963 Free PMC article. Clinical Trial.
Real-world study of everolimus in advanced progressive neuroendocrine tumors.
Panzuto F, Rinzivillo M, Fazio N, de Braud F, Luppi G, Zatelli MC, Lugli F, Tomassetti P, Riccardi F, Nuzzo C, Brizzi MP, Faggiano A, Zaniboni A, Nobili E, Pastorelli D, Cascinu S, Merlano M, Chiara S, Antonuzzo L, Funaioli C, Spada F, Pusceddu S, Fontana A, Ambrosio MR, Cassano A, Campana D, Cartenì G, Appetecchia M, Berruti A, Colao A, Falconi M, Delle Fave G. Panzuto F, et al. Among authors: berruti a. Oncologist. 2014 Sep;19(9):966-74. doi: 10.1634/theoncologist.2014-0037. Epub 2014 Aug 12. Oncologist. 2014. PMID: 25117065 Free PMC article. Clinical Trial.
Real-world study of everolimus in advanced progressive neuroendocrine tumors.
Panzuto F, Rinzivillo M, Fazio N, de Braud F, Luppi G, Zatelli MC, Lugli F, Tomassetti P, Riccardi F, Nuzzo C, Brizzi MP, Faggiano A, Zaniboni A, Nobili E, Pastorelli D, Cascinu S, Merlano M, Chiara S, Antonuzzo L, Funaioli C, Spada F, Pusceddu S, Fontana A, Ambrosio MR, Cassano A, Campana D, Cartenì G, Appetecchia M, Berruti A, Colao A, Falconi M, Delle Fave G. Panzuto F, et al. Among authors: berruti a. Oncologist. 2015 May;20(5):570. doi: 10.1634/theoncologist.2014-0037erratum. Oncologist. 2015. PMID: 25956900 Free PMC article. No abstract available.
Regression of advanced neuroendocrine tumors among patients receiving placebo.
Amoroso V, Agazzi GM, Roca E, Fazio N, Mosca A, Ravanelli M, Spada F, Maroldi R, Berruti A. Amoroso V, et al. Among authors: berruti a. Endocr Relat Cancer. 2017 Feb;24(2):L13-L16. doi: 10.1530/ERC-16-0475. Epub 2016 Dec 13. Endocr Relat Cancer. 2017. PMID: 27965278 No abstract available.
Systemic therapies in patients with advanced well-differentiated pancreatic neuroendocrine tumors (PanNETs): When cytoreduction is the aim. A critical review with meta-analysis.
Pozzari M, Maisonneuve P, Spada F, Berruti A, Amoroso V, Cella CA, Laffi A, Pellicori S, Bertani E, Fazio N. Pozzari M, et al. Among authors: berruti a. Cancer Treat Rev. 2018 Dec;71:39-46. doi: 10.1016/j.ctrv.2018.10.008. Epub 2018 Oct 13. Cancer Treat Rev. 2018. PMID: 30352319 Review.
Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Pavel M, Öberg K, Falconi M, Krenning EP, Sundin A, Perren A, Berruti A; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Pavel M, et al. Among authors: berruti a. Ann Oncol. 2020 Jul;31(7):844-860. doi: 10.1016/j.annonc.2020.03.304. Epub 2020 Apr 6. Ann Oncol. 2020. PMID: 32272208 Free article. No abstract available.
Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): a study protocol.
Bongiovanni A, Liverani C, Pusceddu S, Leo S, Di Meglio G, Tamberi S, Santini D, Gelsomino F, Pucci F, Berardi R, Lolli I, Bergamo F, Ricci S, Foca F, Severi S, Ibrahim T; SENECA Study Team Investigators. Bongiovanni A, et al. BMJ Open. 2020 Jul 19;10(7):e034393. doi: 10.1136/bmjopen-2019-034393. BMJ Open. 2020. PMID: 32690499 Free PMC article.
534 results